Press Release:

MILabs continues to push the limits in multimodal preclinical imaging. Its new integrated hexamodal imaging platform will be unveiled on June 10 at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Denver.

MILabs B.V. launches its next generation integrated PET-SPECT-OI-CT imaging solution – named the 5-series – at the 2017 Annual SNMMI Meeting in Denver, USA that will be held from June 10th to 14th (www.snmmi.org). This fully scalable and integrated PET-SPECT-OI-CT imaging solution is expected to enable even more significant breakthroughs in anatomical, functional and molecular imaging. Building on MILabs’ tradition of offering groundbreaking biomedical imaging innovations, the new 5-series outperforms any other commercially available PET and SPECT system in terms of resolution, multi-modal functionality and multi-tracer performance. Moreover, the system pushes the limits of X-ray CT performance that can be achieved with hybrid PET/CT, SPECT/CT and Optical/CT configurations. It combines ultra-high resolution 4D CT capabilities at very low radiation doses with 0.15 mm SPECT and 0.6 mm PET and offers in combination with the Optical Imaging module, Bioluminescence, Fluorescence and Cherenkov images with unprecedented morphological details. Systems will be available as stand-alone single-modality units or as an integrated multi-modal system with any possible combination of the mentioned modalities.  All imaging modalities can be run on small animals with a single dose of anesthesia.

PET-SPECT-OI-CT imaging solution is expected to enable even more significant breakthroughs in anatomical, functional and molecular imaging

In terms of nuclear molecular imaging, MILabs differentiates its products from conventional systems by magnified physical collimation. With proven performance in over 60 installations worldwide, its latest implementation of PET detection enhances F-18 resolution to nearly the theoretical physical limit and reduces image noise to extremely low levels by eliminating random coincidences and cutting background scatter. Compared to traditional digital PET systems, its PET system is also extremely quiet since only very basic detector cooling is required to minimize noise and crystals with high-energy resolution can be used to further improve S/N.  Moreover, PET and SPECT feature enhanced reconstruction methods that effectively improve resolution and in addition, enable to recover very low concentration of tracers, thus effectively boosting sensitivity for exactly those applications where it really matters. Since high-resolution SPECT has applications beyond in vivo imaging, MILabs is now also offering a multi-isotope 3D autoradiography option with <150 micron image resolution, which enables to rapidly perform autoradiography of tissue samples without slicing, thus reducing ex vivo tissue processing labor time with orders of magnitude.

The proven high quality of MILabs’ X-ray CT system introduced in 2016 has further been enhanced with hybrid Optical/CT imaging, a further reduction in required X-ray radiation dose, improved resolution for both in vivo and ex vivo imaging, pre-scan dose monitoring, and new multi-energy plus dynamic contrast imaging capabilities. The CT subsystem is offered with a choice of three levels of resolution and the high-resolution versions add significant diagnostic value for application areas such as for in vivo bone, vascular, lung, cancer and arthritis research.

“Today our customers are highly enthusiastic about MILabs’ fully integrated PET/SPECT/CT and we are pleased to offer them further improved resolution, quantitative accuracy, low dose and ultra-fast dynamic imaging capabilities as well“, says Frederik Beekman, CEO/CSO of MILabs. This breakthrough brings MILabs even further ahead in terms of combined ultra-high resolution functional and anatomical imaging. MILabs expects that this new generation integrated and highly versatile molecular and anatomical imaging platform will further accelerate the rapid growth of MILabs’ global customer base.

About MILabs

MILabs B.V. (Utrecht, the Netherlands) provides high-end molecular imaging solutions for biomedical and pharmaceutical research. Today these systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac and neurodegenerative diseases. For more information, visit www.milabs.com

Share on social media
Share on facebook
Share on twitter
Share on linkedin
Share on email

Spotlight on the Orthopedic Imaging at UMC Utrecht, the Netherlands – Prof. Harrie Weinans & Dr. Bart van der Wal

  – Spotlight on the Orthopedic Imaging at UMC Utrecht, the Netherlands –  – Prof. …

Read More →

Press Release: MILABS launches its 7th generation of preclinical imagers at the World Molecular Imaging Conference 2021

Under the new ownership of the Rigaku Group (Tokyo, Japan), MILabs is pushing the value …

Read More →

Press Release: RIGAKU Acquires Life Science Imaging Equipment Manufacturer MILabs

August 3, 2021 – Houten, the Netherlands Dear readers, We are very excited that MILabs …

Read More →

Press Release: Confocal PET Causes Spectral PET Breakthrough in Preclinical Imaging

Houten, the Netherlands – March 24, 2021 Using its unique Confocal PET technology, MILabs B.V …

Read More →

Spotlight on Akiva Mintz, MD, Ph.D. – Columbia University

Spotlight on Akiva Mintz, MD, Ph.D. – Columbia University – Bridging the “valley of death” …

Read More →

Spotlight on Bart Cornelissen, PhD – Department of Oncology, Oxford Institute for Radiation Oncology at University of Oxford

– Targeting Tumors from the inside –   Dr. Bart Cornelissen is Group Leader and …

Read More →

Spotlight on Prof. Twan Lammers – ExMI-RWTH Aachen

A Pioneering Mind in Nanomedicine and Theranostics Prof. Dr. Dr. Twan Lammers is Head of …

Read More →

Miltenyi Biotec strengthens its research capabilities for cell analysis and preclinical imaging by acquiring a MILabs’ premium Optical/CT imaging system

  Utrecht and Bergisch Gladbach, September 9, 2020 Miltenyi Biotec B.V. & Co. KG, a …

Read More →

MILabs announced the co-winners of the 2020 MILabs Image of the Year Award

September 4, 2020, Utrecht, The Netherlands Each year, at the occasion of the Annual Congress …

Read More →

Bayer AS installs top-of-the-line MILabs VECTor PET/SPECT/CT to advance its targeted alpha therapy programs

August 27, 2020, Oslo-Norway and Utrecht-The Netherlands Bayer AS has installed a state-of-the-art MILabs VECTor …

Read More →

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam On the frontline of fighting …

Read More →

The University of Southampton enters the field of Correlative In-Vivo Imaging by Acquiring MILabs 3D/4D Optical/CT

May 12, 2020, Southampton, UK – Utrecht, the Netherlands The Faculty of Medicine, University of …

Read More →
Scroll to Top